Venetoclax
Common brands: Venclexta, Vidaza, Onureg, Azacitidine, Azacitidine Azacitidine
Top reporter: Abbvie Inc.
BCL-2 Inhibitor [EPC]Nucleoside Metabolic Inhibitor [EPC]Xanthine Oxidase Inhibitor [EPC]CD20-directed Cytolytic Antibody [EPC]Corticosteroid [EPC]
59,616
Total Reports
44,886
Serious Reports
16,938
Death Reports
30
Reported Reactions
Death Report Ratio: High (28.41%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Venetoclax.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | DEATH | 9,996 | |
| 2 | OFF LABEL USE | 6,655 | |
| 3 | NEUTROPENIA | 3,339 | |
| 4 | FEBRILE NEUTROPENIA | 3,033 | |
| 5 | PLATELET COUNT DECREASED | 2,723 | |
| 6 | PYREXIA | 2,658 | |
| 7 | PNEUMONIA | 2,605 | |
| 8 | FATIGUE | 2,546 | |
| 9 | MYELOSUPPRESSION | 2,438 | |
| 10 | DIARRHOEA | 2,308 | |
| 11 | WHITE BLOOD CELL COUNT DECREASED | 2,194 | |
| 12 | NAUSEA | 2,060 | |
| 13 | THROMBOCYTOPENIA | 2,043 | |
| 14 | INFECTION | 1,926 | |
| 15 | ANAEMIA | 1,881 | |
| 16 | ACUTE MYELOID LEUKAEMIA | 1,803 | |
| 17 | ASTHENIA | 1,728 | |
| 18 | COVID-19 | 1,640 | |
| 19 | HAEMOGLOBIN DECREASED | 1,566 | |
| 20 | DRUG INEFFECTIVE | 1,534 | |
| 21 | DISEASE PROGRESSION | 1,433 | |
| 22 | HOSPITALISATION | 1,305 | |
| 23 | SEPSIS | 1,303 | |
| 24 | PANCYTOPENIA | 1,229 | |
| 25 | ATRIAL FIBRILLATION | 1,154 | |
| 26 | TUMOUR LYSIS SYNDROME | 1,120 | |
| 27 | CYTOPENIA | 1,108 | |
| 28 | NEUTROPHIL COUNT DECREASED | 1,085 | |
| 29 | HOSPICE CARE | 1,051 | |
| 30 | DYSPNOEA | 1,046 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.